Related Experiment Video
Updated: Jun 24, 2026
04:47
Du-Moxibustion in a Mouse Model of Ankylosing Spondylitis
Published on: October 27, 2023
[Azathioprine in inflammatory bowel disease]
Sílvia Leite1, José Manuel Ribeiro, Salomé C Lima
1Serviço de Gastrenterologia, Centro Hospitalar do Alto Ave, Guimarães.
Acta Medica Portuguesa
|April 4, 2009
Summary
Azathioprine (AZA) is a safe and effective long-term treatment for Inflammatory Bowel Disease (IBD), demonstrating significant efficacy in achieving and maintaining clinical remission, particularly within the first 12 months of treatment.
Area of Science:
- Gastroenterology
- Immunosuppressive therapy
- Inflammatory Bowel Disease (IBD)
Context:
- Inflammatory Bowel Disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), presents significant management challenges.
- Azathioprine (AZA) is an established immunosuppressive agent used in IBD treatment.
- Understanding the long-term safety and efficacy profile of AZA in a real-world clinical setting is crucial for optimizing patient care.
Purpose:
- To characterize an Inflammatory Bowel Disease (IBD) patient cohort undergoing azathioprine (AZA) treatment.
- To evaluate the safety and efficacy of AZA in managing IBD.
- To assess AZA's effectiveness in achieving and maintaining clinical remission in steroid-dependent/refractory disease, postoperative recurrence prevention, and other indications.
Summary:
- A retrospective analysis of 30 IBD patients treated with AZA revealed a 75% clinical remission rate at six months for those completing treatment.
- Adverse events occurred in 33.3% of patients, necessitating treatment discontinuation in 13.3%.
- Sustained remission rates at 12 months were 87.5%, with diminishing efficacy beyond 24 months for certain indications.
Impact:
- Azathioprine (AZA) demonstrates favorable safety and efficacy for long-term Inflammatory Bowel Disease (IBD) management.
- AZA is effective in both inducing and maintaining clinical remission, particularly within the first year of therapy.
- The findings support AZA's continued role in the treatment of steroid-dependent/refractory IBD and for preventing postoperative recurrence in Crohn's disease.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...